Audit: QRS - Iberin for Health & Longevity
Audit conducted on 28/08/2026 15:07 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every populated span traces to ER text: protocol cells to Therapeutic Protocol (ER 289-297), time cells to ER 293-295 and 338, gates to ER 245-267, benefits/risks to ER 139-227, monitoring rows to the ER biomarker table (ER 366-373), qualitative items to ER 377-381. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | [time_3_sub] carries “No clinical outcome has ever been observed, so no meaningful time-to-benefit can be stated for iberin at all” verbatim from ER 338; [at_a_glance] carries “Nothing has been tested against a health outcome in a person” mirroring ER 405. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | “Pregnant and breastfeeding women” remains in the Contraindications gate, not the Key Interactions gate; hypothyroidism, peptic ulceration and CKD keep their ER thresholds unchanged. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | All eight [caution_items] come from the ER’s interaction bullets (ER 245-259) and all five [stop_items] from “Populations who should avoid Iberin” (ER 263-267); nothing is drawn from Benefit-Modifying Factors or Risk-Modifying Factors. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, no NCT identifiers and no brand names (Avmacol/Prostaphane) appear; “Johns Hopkins” in [action_2_label] is the ER’s own bold label at ER 289. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution appears that is absent from the ER. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Reserved, mechanism-first, explicitly-limited framing matching the ER throughout. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Quantified thresholds and targets throughout; the Protocol panel gives an actionable whole-food route despite the thin evidence base. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Gate and monitoring content is stated in nominal form (“Baseline panel before starting…”), not as instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No modal or imperative advisory constructions; the only “should” (line 742) is inside an ER-verbatim qualitative marker. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No occurrence of “recommend”, “advise”, “ensure”, “consult” or equivalent in document voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronoun anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Abbreviations are confined to the Monitoring marker column where they are the ER’s own row labels; contraindications spell out “thyroid-stimulating hormone” and “estimated glomerular filtration rate”. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Gate items are bare noun phrases; benefits and risks are semicolon-joined headline facts with no elaboration. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed; no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Optimal-range targets (hs-CRP below 0.5 mg/L, ALT below 20/17 U/L) rather than conventional reference limits address the optimizing reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | An eight-marker panel, repeat thyroid testing and 3-5 daily cruciferous servings assume a high-effort reader. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content is pitched well above general-population health messaging. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The sheet foregrounds that only exposure, not benefit, is established — the distinction that matters to an early-adopter reader. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “anti-aging” does not occur; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | “erosive esophagitis”, “renal tubular secretion”, “isothiocyanate conjugates” and similar formal register throughout. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” |
🟢 | All headings match the template byte-for-byte (lines 444, 484, 528, 547, 561, 581, 600, 721); “Low: “ and “Speculative: “ tier labels are unmodified, and the High/Medium list items are removed only as item 12.5/13.5 requires. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template variable names are present; marker_# and qualitative_item_# are expanded to the eight and five concrete instances the content requires. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A structural diff against the template shows no change outside the variable spans, the metadata block and the sanctioned display:none attributes. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; the High and Medium benefit/risk tiers carry explanatory prose rather than an empty state, and are handled under items 12.5 and 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | [action_1_label] “The whole-food alternative”, [action_2_label] “The Johns Hopkins broccoli sprout approach” and [action_3_label] “Split versus single dosing” reproduce the ER bold labels at ER 291, 289 and 297 exactly; monitoring row labels reproduce the ER table’s biomarker names. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Protocol, monitoring and gate labels are ER text; the Time-to-Effect cell labels name the aspects the ER bullets describe, as item 11.4 provides for. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji present; the ER’s “⚠️ Conflicted” markers on the Nrf2 benefit and the thyroid risk are correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content sits within the template’s per-section budget: three protocol cells, three time cells, five gate items, eight one-line interactions, single-line tier summaries, and the eight monitoring rows and five qualitative markers that items 14.2 and 15.2 mandate. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Lines 2-14; the comment opens immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- on line 3, closing --- on line 13; the descriptive text on line 2 precedes the opening delimiter. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment and not duplicated anywhere in the body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, correctly so because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: iberin_2026-0828-1344_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0828-1454, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version with no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: iberin_2026-0828-1344_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Iberin for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Iberin for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “08/28/2026”, correctly derived from qrs_creation_date: 2026-0828-1454. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | The header carries only the title and the template subline; the ER’s “Also known as” line is not reproduced. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Lines 433-437 condense ER 403-405 to what it is, how it acts, where the evidence comes from, and the decision-relevant fact that no human outcome has been tested. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Sentence 1 ← ER 403; sentence 2 ← ER 403; sentence 3 ← ER 405; sentence 4 ← ER 405 (“None of that has been tested against a health outcome in a person”). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “reactive sulfur compound”, “cells in culture” and “waste-clearing programs” are the ER Conclusion’s own plain-language renderings. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric result of any kind appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All five items map to “Populations who should avoid Iberin” at ER 261-267. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-populations are represented, none omitted and none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Lines 550-556: five <li> elements inside the [stop_items] span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER “since/for whom/because” rationale clause is stripped (e.g. ER 263 “…, since every commercial source is labelled not for human consumption…” → “Anyone considering isolated iberin from a chemical supplier”). |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(thyroid-stimulating hormone above 10 mIU/L)”, “below 100 µg/day”, “(Los Angeles grade C or D)” and “(estimated glomerular filtration rate below 30 mL/min/1.73 m²)” are all retained. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s contraindication parentheticals use spelled-out comparators (“above 10 mIU/L”, “below 30 mL/min/1.73 m²”) and a named staging class; no ranking notation is used. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does identify avoid-populations, so the constraint holds. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items map to the ER interaction bullets at ER 245-259. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight ER interaction bullets are present and none duplicates a Contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Lines 564-571: eight <li> elements inside the [caution_items] span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Severity words, mechanism, mitigation text and the Gong/Wang/Nowicki citations are all stripped; each item is the bare agent or exposure. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All five ER example-drug lists are carried through intact: NAC/glutathione/alpha-lipoic acid; sulforaphane/erucin/alyssin/iberverin; warfarin/acenocoumarol/phenprocoumon; levothyroxine/liothyronine; omeprazole/calcium carbonate. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction parentheticals are plain comma-separated drug lists with no ranking notation. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does identify interactions, so the constraint holds. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol bullets at ER 289, 291 and 297. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose form and amount (whole-food route), the quantified extract regimen, and dose distribution — the only three bullets in the ER Therapeutic Protocol that carry an executable instruction. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies more than three actionable implementation aspects and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | Nine of nine spans carry substantive ER-derived content; “3-5 servings daily” ← ER 291, “25-100 µmol every 8 hours” ← ER 289, “Split across meals” ← ER 293/297. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Systemic exposure (ER 293/295), enzyme induction (ER 338) and clinical benefit (ER 338) are the only three time horizons the ER supplies. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Correct descending order: systemic exposure is the ER’s only Low-tier (highest-rated) benefit, enzyme induction is Speculative, and clinical benefit has no tier at all. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | Nine of nine spans carry ER-derived content; [time_1_sub] merges the ER’s peak-time and half-life statements, [time_2_sub] and [time_3_sub] split the ER’s “Time to effect” bullet at ER 338. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER 293-295, 338), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Both populated tiers map to ER 129-165. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 530-540. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of the ER’s benefit headings; the 19-29% urinary recovery figure, the 0.94-2.27 µmol/L plasma peak and the Ernst/Shibata/Gong/Jakobsen/Yahiya citations are all stripped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in [benefits_low] or [benefits_speculative]. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER records no High and no Medium benefit; lines 530-531 set both spans to style="display: none" with no empty-state text. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Both populated tiers map to ER 189-227. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 583-594. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Both tiers reduce to the ER’s risk headings; the Shapiro, Chartoumpekis, Steverding, Jakubikova and Wang citations and all magnitude prose are stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses appear in [risks_low] or [risks_speculative]. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER records no High and no Medium risk; lines 583-584 set both spans to style="display: none" with no empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Rows map one-to-one to the ER Monitoring Protocol & Defining Success biomarker table at ER 366-373. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eight are present in ER order: TSH, Free T4, TPO antibodies, hs-CRP, GGT, ALT, eGFR, urinary isothiocyanate conjugates — with targets and rationales reproduced verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 712-715 reproduce the ER’s schedule at ER 362 and 368: baseline panel, thyroid at 12 weeks then 6 and 12 months, other markers every 6 to 12 months, TPO once at baseline. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All five items map to the ER’s “Qualitative markers worth tracking” list at ER 377-381. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five are present verbatim and in ER order: upper GI comfort, bloating and flatulence, cold intolerance/fatigue/dry skin, energy and cognitive clarity, sleep quality. |
Issues 28/08/2026 15:07
Pass rate 100.00%. No issues found.
Issues 28/08/2026 15:00
- 9.4 — Trailing clause after hyphen-dash: The last Key Interactions item at line 571, “Other interventions - fasting and ketogenic protocols”, carries content after a hyphen-dash, which item 9.4 requires to be stripped.
Fixes 28/08/2026 15:00
- 9.4 — Trailing clause after hyphen-dash: Replaced the Key Interactions item “Other interventions - fasting and ketogenic protocols” with “Fasting and ketogenic protocols”, dropping the vacuous prefix and the hyphen-dash so only the key fact remains.